Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker LYEL
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 416 | $15.93 | $6,627 Sale | Form 4 ↗ |
| Nov 10, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 129 | $15.93 | $2,055 Sale | Form 4 ↗ |
| Nov 10, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 88 | $15.93 | $1,402 Sale | Form 4 ↗ |
| Nov 10, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 545 | $15.93 | $8,682 Sale | Form 4 ↗ |
| Nov 4, 2026 | ARCH Venture Partners IX, LLC 10% owner | LYEL Lyell Immunopharma, Inc. | Buy | 2.32M | $10.77 | $25.0M Buy | Form 4 ↗ |
| Nov 4, 2026 | ARCH Venture Fund XIII, L.P. 10% owner | LYEL Lyell Immunopharma, Inc. | Buy | 2.32M | $10.77 | $25.0M Buy | Form 4 ↗ |
| Sep 10, 2026 | David Shook Chief Medical Officer | LYEL Lyell Immunopharma, Inc. | Sale | 500 | $12.70 | $6,350 Sale | Form 4 ↗ |
| Aug 21, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,457 | $15.54 | $22.6K Sale | Form 4 ↗ |
| Aug 21, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 989 | $15.54 | $15.4K Sale | Form 4 ↗ |
| Aug 21, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 9,589 | $15.54 | $149.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 621 | $14.34 | $8,905 Sale | Form 4 ↗ |
| Aug 10, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 131 | $14.34 | $1,879 Sale | Form 4 ↗ |
| Aug 10, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 89 | $14.34 | $1,276 Sale | Form 4 ↗ |
| Aug 10, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 390 | $14.34 | $5,593 Sale | Form 4 ↗ |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | LYEL Lyell Immunopharma, Inc. | Sale | 10 | $13.70 | $137 Sale | Form 4 ↗ |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | LYEL Lyell Immunopharma, Inc. | Sale | 10 | $13.73 | $137 Sale | Form 4 ↗ |
| Jun 10, 2026 | David Shook Chief Medical Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,977 | $12.64 | $25.0K Sale | Form 4 ↗ |
| May 11, 2026 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 217 | $18.91 | $4,103 Sale | Form 4 ↗ |
| May 11, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 130 | $18.92 | $2,460 Sale | Form 4 ↗ |
| May 11, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 89 | $18.92 | $1,684 Sale | Form 4 ↗ |
| May 11, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 388 | $18.91 | $7,337 Sale | Form 4 ↗ |
| Mar 6, 2026 | ARCH Venture Partners IX Overage, L.P. 10% owner | LYEL Lyell Immunopharma, Inc. | Buy | 488,090 | $25.61 | $12.5M Buy | Form 4 ↗ |
| Mar 6, 2026 | Paul L. Berns 10% owner | LYEL Lyell Immunopharma, Inc. | Buy | 488,090 | $25.61 | $12.5M Buy | Form 4 ↗ |
| Feb 11, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,671 | $23.39 | $39.1K Sale | Form 4 ↗ |
| Feb 11, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,236 | $23.39 | $28.9K Sale | Form 4 ↗ |
| Feb 11, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 7,455 | $23.39 | $174.4K Sale | Form 4 ↗ |
| Feb 10, 2026 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 254 | $23.12 | $5,872 Sale | Form 4 ↗ |
| Feb 10, 2026 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 147 | $23.12 | $3,399 Sale | Form 4 ↗ |
| Feb 10, 2026 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 109 | $23.12 | $2,520 Sale | Form 4 ↗ |
| Feb 10, 2026 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 438 | $23.12 | $10.1K Sale | Form 4 ↗ |
| Dec 30, 2025 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 936 | $32.32 | $30.3K Sale | Form 4 ↗ |
| Dec 24, 2025 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 1,136 | $38.67 | $43.9K Sale | Form 4 ↗ |
| Nov 10, 2025 | Veronica Sanchez Bulis VP, Corporate Controller | LYEL Lyell Immunopharma, Inc. | Sale | 239 | $16.10 | $3,848 Sale | Form 4 ↗ |
| Nov 10, 2025 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 138 | $16.16 | $2,230 Sale | Form 4 ↗ |
| Nov 10, 2025 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 95 | $16.12 | $1,531 Sale | Form 4 ↗ |
| Nov 10, 2025 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 412 | $16.11 | $6,637 Sale | Form 4 ↗ |
| Aug 21, 2025 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 7,257 | $10.54 | $76.5K Sale | Form 4 ↗ |
| Aug 21, 2025 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,004 | $10.54 | $10.6K Sale | Form 4 ↗ |
| Aug 21, 2025 | Charles W. Newton Chief Financial Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,453 | $10.54 | $15.3K Sale | Form 4 ↗ |
| Aug 21, 2025 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 1,453 | $10.54 | $15.3K Sale | Form 4 ↗ |
| Aug 12, 2025 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 406 | $10.34 | $4,198 Sale | Form 4 ↗ |
| Aug 12, 2025 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 94 | $10.34 | $972 Sale | Form 4 ↗ |
| Aug 12, 2025 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 136 | $10.34 | $1,406 Sale | Form 4 ↗ |
| Aug 12, 2025 | Charles W. Newton Chief Financial Officer | LYEL Lyell Immunopharma, Inc. | Sale | 136 | $10.34 | $1,406 Sale | Form 4 ↗ |
| Aug 11, 2025 | Lynn Seely President and CEO, Director | LYEL Lyell Immunopharma, Inc. | Sale | 391 | $10.53 | $4,117 Sale | Form 4 ↗ |
| Aug 11, 2025 | Stephen J. Hill Chief Operating Officer | LYEL Lyell Immunopharma, Inc. | Sale | 91 | $10.53 | $958 Sale | Form 4 ↗ |
| Aug 11, 2025 | Gary K. Lee Chief Scientific Officer | LYEL Lyell Immunopharma, Inc. | Sale | 131 | $10.53 | $1,379 Sale | Form 4 ↗ |
| Aug 11, 2025 | Charles W. Newton Chief Financial Officer | LYEL Lyell Immunopharma, Inc. | Sale | 131 | $10.53 | $1,379 Sale | Form 4 ↗ |
| Mar 31, 2025 | Otis W. Brawley Director | LYEL Lyell Immunopharma, Inc. | Buy | 35,640 | $0.56 | $20.0K Buy | Form 4 ↗ |
| Mar 21, 2025 | Sumant Ramachandra Director | LYEL Lyell Immunopharma, Inc. | Buy | 200,000 | $0.58 | $116.0K Buy | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances